The use of the tracer methodology to assess the quality of care for patients enrolled in Medical Insurance for a New Generation

Durán-Arenas, Luis; Muñoz‐Hernández, Onofre; Hernández-Ramírez, Luz del Carmen; Jasso-Gutiérrez, Luís; Flores, Samuel; Aldaz-Rodríguez, Vanessa; Zurita, Juan Manuel

doi:10.1590/s0036-36342012000700007

Cited by 6 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The co-existence of two different main public healthcare delivery systems (IMSS and SS) is not the only factor that may hamper extrapolation of cost data. In Mexico, the effectiveness of the healthcare sectors has been questioned after multiple reforms have been enacted [ 25 ], with patients not always receiving optimal treatment. In particular, the SS healthcare sector, which provides coverage through ‘Popular Insurance’, has suffered from suboptimal funding and fragmented organization (in reality there are 32 different healthcare systems–one for each state in the country) [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

Calculation of the Average Cost per Case of Dengue Fever in Mexico Using a Micro-Costing Approach

Zubieta-Zavala¹,

Salinas-Escudero²,

Ramírez-Chávez³

et al. 2016

PLoS Negl Trop Dis

Self Cite

View full text Add to dashboard Cite

IntroductionThe increasing burden of dengue fever (DF) in the Americas, and the current epidemic in previously unaffected countries, generate major costs for national healthcare systems. There is a need to quantify the average cost per DF case. In Mexico, few data are available on costs, despite DF being endemic in some areas. Extrapolations from studies in other countries may prove unreliable and are complicated by the two main Mexican healthcare systems (the Secretariat of Health [SS] and the Mexican Social Security Institute [IMSS]). The present study aimed to generate specific average DF cost-per-case data for Mexico using a micro-costing approach.MethodsExpected medical costs associated with an ideal management protocol for DF (denoted ´ideal costs´) were compared with the medical costs of current treatment practice (denoted ´real costs´) in 2012. Real cost data were derived from chart review of DF cases and interviews with patients and key personnel from 64 selected hospitals and ambulatory care units in 16 states for IMSS and SS. In both institutions, ideal and real costs were estimated using the program, actions, activities, tasks, inputs (PAATI) approach, a micro-costing technique developed by us.ResultsClinical pathways were obtained for 1,168 patients following review of 1,293 charts. Ideal and real costs for SS patients were US$165.72 and US$32.60, respectively, in the outpatient setting, and US$587.77 and US$490.93, respectively, in the hospital setting. For IMSS patients, ideal and real costs were US$337.50 and US$92.03, respectively, in the outpatient setting, and US$2,042.54 and US$1,644.69 in the hospital setting.ConclusionsThe markedly higher ideal versus real costs may indicate deficiencies in the actual care of patients with DF. It may be necessary to derive better estimates with micro-costing techniques and compare the ideal protocol with current practice when calculating these costs, as patients do not always receive optimal care.

show abstract

Section: Introductionmentioning

confidence: 99%

Calculation of the Average Cost per Case of Dengue Fever in Mexico Using a Micro-Costing Approach

Zubieta-Zavala¹,

Salinas-Escudero²,

Ramírez-Chávez³

et al. 2016

PLoS Negl Trop Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Bookbinde et al (7) 2018 USA Journal of Pain and Symptom Management CINAHL Ross et al (8) 2017 USA Military Medicine CINAHL Smith (9) 2014 USA Social Science & Medicine CINAHL Meade et al (10) 2015 USA Journal of Community Hospital Internal Medicine Perspectives Medline/PubMed Oliveira, Guljor, Verztman (11) 2015 Brazil Revista Latinoamericana de Psicopatologia Fundamental LILACS Chaves et al (12) 2015 Brazil Saúde & Sociedade LILACS Durán-Arenas et al (13) 2012 Mexico Salud Pública de México LILACS Pacheco-Domínguez et al (14) 2011 Mexico Salud Pública de México LILACS Bottari et al (15) 2008 Brazil Cadernos de Saúde Pública LILACS Silva et al (16) 2010 Brazil Revista de Saúde Pública SciELO…”

Section: Author Year Country Periodical Databasementioning

confidence: 99%

“…Regarding the 22 articles analyzed in this study: seven use a quantitative approach (7,9,(12)(13)(14)16,19), seven use a mixed method (quanti-qualitative) (8,15,(17)(18)(20)(21)27) , five have a qualitative approach (3,(10)(11)22,24) and three are reports of experiences (23,(25)(26) .…”

Section: Author Year Country Periodical Databasementioning

confidence: 99%

“…The data collection techniques reported in these articles were documentary analysis patient records and exams (3,(7)(8)(9)(10)(12)(13)(16)(17)(19)(20)(21)27), , face-to-face and online intervie ws (3,(7)(8)(9)(10)(12)(13)(16)(17)(19)(20)(21)27), observation (8)(9)16) and a focus group (15) . Most studies relied on multiple sources of evidence.…”

Section: Author Year Country Periodical Databasementioning

confidence: 99%

“…The individuals who participated in the studies were health professionals, users and manager (6,8,(14)(15)(16)(17) , only health professionals (9,13,19) or only users (7,10) .…”

Section: Author Year Country Periodical Databasementioning

confidence: 99%

See 2 more Smart Citations

Método Tracer e a qualidade do cuidado na enfermagem: revisão integrativa da literatura

Meireles

Labegalini

Baldissera

2019

Rev. Gaúcha Enferm.

View full text Add to dashboard Cite

Resumo OBJETIVO Analisar a produção científica sobre o Método Tracer na área da enfermagem. MÉTODO Revisão integrativa, realizada com 22 artigos localizados nas bases de dados: Literatura Latino-Americana e do Caribe em Ciências e Saúde (LILACS); Medical Literature Analysis and Retrieval System Online(Medline/PubMed); Scientific Eletronic Library Online (SciELO); Cumulative Index to Nursing & Allied Health Literature (CINAHL) eWeb of Science. As estratégias de busca incluíram descritores e palavras-chave: Método Tracer, Método traçador, Método rastreador, Método de avaliação, Usuário Guia e Enfermagem correlacionados e combinados com operadores booleanos. RESULTADOS Organizaram-se os dados segundo os cenários de aplicação do método, a saber: agravos à saúde como condição traçadora para avaliar a qualidade dos cuidados, conformidades e não conformidades em relação aos protocolos institucionais, reflexão e capacitação para a acreditação. CONCLUSÃO O Método Tracer é utilizado para avaliação e melhoria da qualidade da assistência.

show abstract

A Novel Private–Public Hybrid Model for Treatment of Congenital Heart Disease in Mexico

Palacios-Macedo

Mery

Cabrera

et al. 2019

World J Pediatr Congenit Heart Surg

View full text Add to dashboard Cite

Mortality after surgery for congenital heart disease (CHD) in Mexico is significantly higher than in high-income countries due to structural, medical, and financial factors. In Mexico, public hospitals have a large volume of patients but inadequate quality control systems, whereas private hospitals, although having higher quality control systems, have an insufficient number of patients to build programs of excellence. We describe the creation of a novel hybrid private-public program in Mexico that leverages the advantages of both sectors while establishing an integrated multidisciplinary unit that has allowed us to improve the quality of care for patients with CHD.

show abstract

The use of the tracer methodology to assess the quality of care for patients enrolled in Medical Insurance for a New Generation

Cited by 6 publications

References 6 publications

Calculation of the Average Cost per Case of Dengue Fever in Mexico Using a Micro-Costing Approach

Calculation of the Average Cost per Case of Dengue Fever in Mexico Using a Micro-Costing Approach

Método Tracer e a qualidade do cuidado na enfermagem: revisão integrativa da literatura

A Novel Private–Public Hybrid Model for Treatment of Congenital Heart Disease in Mexico

Contact Info

Product

Resources

About